第四届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉明德生物科技股份有限公司（以下简称"公司"）第四届董事会第二十 二次会议于 2025 年 10 月 17 日以现场及通讯相结合的方式在公司会议室召开， 会议通知已于 2025 年 10 月 13 日以电子邮件、电话通讯等形式发出。本次会议 应到董事 7 名，实际出席会议的董事 7 名，会议由公司董事长陈莉莉女士主持， 公司监事、高级管理人员列席了本次会议，会议的召集和召开符合《中华人民共 和国公司法》（以下简称《公司法》）等法律法规及《公司章程》的规定。 二、董事会会议审议情况 1、审议通过《关于变更注册地址并修订<公司章程>的议案》 证券代码：002932 证券简称：明德生物 公告编号：2025-042 武汉明德生物科技股份有限公司 表决结果：同意票数为 7 票，反对票数为 0 票，弃权票数为 0 票。 本议案尚需提交股东大会审议，并提请股东大会授权公司经营层办理工商变 更登记等相关事宜。公司将在股东大会审议通过该事项后，及时办理相关工商备 案登记 ...

证券日报网讯明德生物（002932）10月13日在互动平台回答投资者提问时表示，截至2025年9月30日， 公司股东总户数为23154户。 ...

证券日报网讯明德生物（002932）9月25日在互动平台回答投资者提问时表示，公司于今年完成了一轮 回购并发布了估值提升计划，后续将根据公司经营和市场情况评估估值提升的措施，未来如有相关进 展，公司将及时履行信息披露义务。 ...

证券日报网讯明德生物9月23日在互动平台回答投资者提问时表示，截至2025年9月19日，公司股东总户 数为23283户。 （文章来源：证券日报） ...

Core Viewpoint - Mindray Bio-Medical Electronics Co., Ltd. emphasizes the importance of objective and rational assessment of its stock price, which is influenced by various factors [1] Group 1 - The company is committed to continuously improving corporate governance and operational management [1] - Mindray aims to enhance its operational performance and core competitiveness [1] - The company strives for high-quality development to create better returns for shareholders [1]

Core Viewpoint - Mingde Biological announced on September 15 that as of September 10, 2025, the total number of shareholders is 23,819 [2] Summary by Categories - **Company Information** - Mingde Biological has a total of 23,819 shareholders as of September 10, 2025 [2] - **Investor Communication** - The company responded to investor inquiries on its interactive platform regarding shareholder numbers [2]

Group 1 - The company Mindray Bio-Medical Electronics (002932) reported that as of August 29, 2025, the total number of shareholders is 23,905 [1]

Group 1 - Mingde Biological (002932.SZ) released its semi-annual report for 2025 on August 28, 2025, showing that as of August 27, 2025, 11 institutional investors held a total of 11.31 million shares, accounting for 4.86% of the total share capital [1] - The top ten institutional investors include major entities such as China Merchants Bank, Bank of China, and China Ping An Life Insurance, with their combined shareholding percentage decreasing by 2.23 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, three funds reported a decrease in holdings compared to the previous quarter, with a total reduction of 0.56% [2] - Four new public funds disclosed their holdings this quarter, including funds focused on dividend indices and medical devices [2] - In the insurance sector, one insurer, China Ping An Life Insurance, reported a slight decrease in holdings compared to the previous quarter [2]

Group 1 - The company Mindray Bio-Medical Electronics announced the convening of its 21st meeting of the 4th board of directors on August 27, 2025, to review the special report on the use of raised funds for the first half of 2025 [1] - The meeting included discussions on the status of fundraising and its application, indicating ongoing financial management and strategic planning [1] Group 2 - The news highlights a significant medical advancement with the world's first successful transplantation of gene-edited pig lungs into a human, raising questions about the timeline for clinical applications [1] - This breakthrough could have implications for the biotechnology and healthcare industries, particularly in organ transplantation and genetic research [1]

Group 1 - The core viewpoint of the article is that Mindray Bio (002932.SZ) reported a decline in both revenue and net profit for the first half of 2025, indicating financial challenges [1] - The company achieved operating revenue of 139 million yuan, a year-on-year decrease of 9.71% [1] - The net profit attributable to shareholders of the listed company was 12.4973 million yuan, reflecting a significant year-on-year decline of 80.82% [1] Group 2 - The net loss attributable to shareholders after deducting non-recurring gains and losses was 35.6218 million yuan, with a year-on-year loss increase of 23.59% [1] - The basic earnings per share were reported at 0.06 yuan [1]